William E. Alborn

3.4k total citations
35 papers, 2.1k citations indexed

About

William E. Alborn is a scholar working on Molecular Biology, Organic Chemistry and Surgery. According to data from OpenAlex, William E. Alborn has authored 35 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 9 papers in Organic Chemistry and 9 papers in Surgery. Recurrent topics in William E. Alborn's work include Lipoproteins and Cardiovascular Health (7 papers), Bacterial Genetics and Biotechnology (6 papers) and Peroxisome Proliferator-Activated Receptors (5 papers). William E. Alborn is often cited by papers focused on Lipoproteins and Cardiovascular Health (7 papers), Bacterial Genetics and Biotechnology (6 papers) and Peroxisome Proliferator-Activated Receptors (5 papers). William E. Alborn collaborates with scholars based in United States and Türkiye. William E. Alborn's co-authors include Norris E. Allen, Robert J. Konrad, J N Hobbs, Guoqing Cao, David A. Preston, Jason S. Troutt, Roslyn Davis, Michael D. Knierman, A. Eric Schultze and Herbert A. Kirst and has published in prestigious journals such as Clinical Cancer Research, Biochemical and Biophysical Research Communications and Journal of Bacteriology.

In The Last Decade

William E. Alborn

35 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William E. Alborn United States 23 882 632 365 328 250 35 2.1k
Alice H. Lin United States 18 782 0.9× 368 0.6× 305 0.8× 144 0.4× 318 1.3× 29 2.0k
K.R. Marotti United States 17 602 0.7× 308 0.5× 299 0.8× 174 0.5× 117 0.5× 30 1.3k
Eva S. Istvan United States 17 1.3k 1.4× 740 1.2× 150 0.4× 363 1.1× 251 1.0× 24 2.9k
Xingpei Hao United States 29 1.2k 1.3× 191 0.3× 144 0.4× 287 0.9× 246 1.0× 63 2.7k
Éric Marsault Canada 27 1.3k 1.4× 467 0.7× 156 0.4× 56 0.2× 704 2.8× 81 2.7k
Michael M. Gottesman United States 14 1.9k 2.2× 419 0.7× 602 1.6× 104 0.3× 180 0.7× 17 4.0k
Lalitha Iyer United States 25 2.4k 2.7× 227 0.4× 292 0.8× 189 0.6× 341 1.4× 52 4.0k
Koji Tomita Japan 29 1.2k 1.4× 278 0.4× 74 0.2× 223 0.7× 634 2.5× 125 2.6k
Maria Chiara Monti Italy 32 1.1k 1.3× 413 0.7× 71 0.2× 162 0.5× 467 1.9× 134 2.7k
Syed Akhtar Husain India 29 1.3k 1.5× 98 0.2× 273 0.7× 442 1.3× 223 0.9× 110 3.1k

Countries citing papers authored by William E. Alborn

Since Specialization
Citations

This map shows the geographic impact of William E. Alborn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Alborn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Alborn more than expected).

Fields of papers citing papers by William E. Alborn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William E. Alborn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Alborn. The network helps show where William E. Alborn may publish in the future.

Co-authorship network of co-authors of William E. Alborn

This figure shows the co-authorship network connecting the top 25 collaborators of William E. Alborn. A scholar is included among the top collaborators of William E. Alborn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William E. Alborn. William E. Alborn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bowton, Erica, Sarah P. Collier, Xiaoming Wang, et al.. (2015). Phenotype-Driven Plasma Biobanking Strategies and Methods. Journal of Personalized Medicine. 5(2). 140–152. 9 indexed citations
2.
Lin, De, William E. Alborn, Robbert J.C. Slebos, & D.C. Liebler. (2013). Comparison of Protein Immunoprecipitation-Multiple Reaction Monitoring with ELISA for Assay of Biomarker Candidates in Plasma. Journal of Proteome Research. 12(12). 5996–6003. 51 indexed citations
3.
Hassanein, Mohamed, Megan D. Hoeksema, Masakazu Shiota, et al.. (2012). SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival. Clinical Cancer Research. 19(3). 560–570. 283 indexed citations
4.
Troutt, Jason S., William E. Alborn, Guoqing Cao, & Robert J. Konrad. (2009). Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. Journal of Lipid Research. 51(2). 345–351. 57 indexed citations
5.
Schmidt, Robert J., Thomas P. Beyer, William R. Bensch, et al.. (2008). Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochemical and Biophysical Research Communications. 370(4). 634–640. 85 indexed citations
6.
Davis, Roslyn, et al.. (2007). Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. Journal of Lipid Research. 49(2). 394–398. 261 indexed citations
7.
Troutt, Jason S., William E. Alborn, Marian Mosior, et al.. (2007). An apolipoprotein A-I mimetic dose-dependently increases the formation of preβ1 HDL in human plasma. Journal of Lipid Research. 49(3). 581–587. 36 indexed citations
8.
Alborn, William E., Guoqing Cao, Yuewei Qian, et al.. (2007). Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol. Clinical Chemistry. 53(10). 1814–1819. 132 indexed citations
9.
Alborn, William E., Melvin Prince, & Robert J. Konrad. (2006). Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes. Clinica Chimica Acta. 378(1-2). 154–158. 17 indexed citations
10.
Lee, Thomas N., William E. Alborn, Michael D. Knierman, & Robert J. Konrad. (2006). Alloxan is an inhibitor of O-GlcNAc-selective N-acetyl-β-d-glucosaminidase. Biochemical and Biophysical Research Communications. 350(4). 1038–1043. 58 indexed citations
11.
Lee, Thomas N., William E. Alborn, Michael D. Knierman, & Robert J. Konrad. (2006). The diabetogenic antibiotic streptozotocin modifies the tryptic digest pattern for peptides of the enzyme O-GlcNAc-selective N-acetyl-β-d-glucosaminidase that contain amino acid residues essential for enzymatic activity. Biochemical Pharmacology. 72(6). 710–718. 12 indexed citations
12.
Schultze, A. Eric, William E. Alborn, Ronald K. Newton, & Robert J. Konrad. (2005). Administration of a PPARα agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio. Journal of Lipid Research. 46(8). 1591–1595. 38 indexed citations
13.
14.
Alborn, William E., JoAnn Hoskins, Serhat Ünal, et al.. (1996). Cloning and characterization of femA and femB from Staphylococcus epidermidis. Gene. 180(1-2). 177–181. 19 indexed citations
15.
16.
Ternansky, Robert J., Susan E. Draheim, Andrew Pike, et al.. (1993). Discovery and structure-activity relationship of a series of 1-carba-1-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus. Journal of Medicinal Chemistry. 36(14). 1971–1976. 27 indexed citations
17.
Jungheim, Louis N., et al.. (1991). Synthesis, hydrolysis rates, supercomputer modeling, and antibacterial activity of bicyclic tetrahydropyridazinones. Journal of Medicinal Chemistry. 34(5). 1732–1739. 28 indexed citations
18.
Allen, Norris E., William E. Alborn, & J N Hobbs. (1991). Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrobial Agents and Chemotherapy. 35(12). 2639–2642. 77 indexed citations
19.
Fukuda, D. S., Jon S. Mynderse, Patrick J. Baker, et al.. (1990). A80915, a new antibiotic complex produced by Streptomyces aculeolatus. Discovery, taxonomy, fermentation, isolation, characterization, and antibacterial evaluation.. The Journal of Antibiotics. 43(6). 623–633. 51 indexed citations
20.
Gordee, Robert S., Douglas J. Zeckner, Leonard C. Howard, William E. Alborn, & Manuel Debono. (1988). Anti‐Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal Antibiotica. Annals of the New York Academy of Sciences. 544(1). 294–309. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alice H. Lin Breakdown of academic impact, for papers by K.R. Marotti Breakdown of academic impact, for papers by Eva S. Istvan Breakdown of academic impact, for papers by Xingpei Hao Breakdown of academic impact, for papers by Éric Marsault Breakdown of academic impact, for papers by Michael M. Gottesman Breakdown of academic impact, for papers by Lalitha Iyer Breakdown of academic impact, for papers by Koji Tomita Breakdown of academic impact, for papers by Maria Chiara Monti Breakdown of academic impact, for papers by Syed Akhtar Husain
Rankless by CCL
2026